What is male factor infertility?
Male factor infertility is a clinical category used when one or more parameters of a male partner's reproductive evaluation fall outside reference ranges associated with natural conception. The category is broad: it spans low sperm concentration, reduced motility, abnormal morphology, problems with sperm DNA integrity, ejaculatory or anatomical issues, hormonal disorders, and genetic conditions such as Y chromosome microdeletions or Klinefelter syndrome.
The first-line evaluation is the semen analysis, performed and interpreted using World Health Organization reference values (currently the 6th edition, published 2021). The American Urological Association and American Society for Reproductive Medicine recommend that men in couples with infertility undergo evaluation in parallel with their female partner — not after — because identifying male contributions early changes the treatment approach.
How common is it among IVF patients?
According to the most recent CDC ART Surveillance Report, male factor is reported as a contributing diagnosis in IVF cycles across nearly every US fertility clinic. Across the dataset on this site, male factor appears as a reported diagnosis at 447 of 458 US clinics, with an estimated 243,801 IVF cycles annually citing male factor as one of the diagnoses.
The high prevalence among IVF patients reflects two realities. First, severe male factor cases that would be unlikely to conceive naturally or with intrauterine insemination are often referred directly to IVF with intracytoplasmic sperm injection (ICSI). Second, CDC reporting allows multiple diagnoses per cycle: a couple may have both male factor and another condition such as diminished ovarian reserve, and both are recorded.
How male factor affects IVF outcomes
When male factor infertility is the primary diagnosis and ICSI is used to achieve fertilization, IVF outcomes are generally similar to outcomes for couples without male factor, provided egg quality is preserved. ICSI directly injects a single selected sperm into each mature egg, bypassing the natural barriers that would prevent fertilization in vitro. This is why severe male factor patients can still achieve normal fertilization rates when ICSI is used.
Several caveats apply. Sperm DNA fragmentation — damage to the genetic material inside sperm — has been associated in some studies with lower implantation rates and higher miscarriage rates, though the clinical utility of routine DNA fragmentation testing remains debated. Severe oligospermia (very low sperm count) and azoospermia (no sperm in the ejaculate) require surgical sperm retrieval procedures such as testicular sperm extraction; in these cases outcomes depend significantly on whether mature sperm can be found, and the underlying cause of azoospermia matters (obstructive vs. non-obstructive).
Live birth rates per intended retrieval shown on this site reflect each clinic's overall performance for all patients, not male-factor-specific outcomes. The CDC does not publish per-diagnosis success rates at the clinic level. For a clinic-specific male factor success conversation, ask the clinic directly.
What treatments are commonly discussed
Treatment approaches for male factor infertility are individualized and depend on the cause and severity. Reproductive specialists may discuss the following options, each appropriate in different clinical scenarios:
- Lifestyle and medical optimization. Smoking cessation, weight management, treatment of varicocele, treatment of hormonal disorders such as hypogonadotropic hypogonadism, and review of medications that affect spermatogenesis.
- Intrauterine insemination (IUI) — sometimes used for mild male factor when the female partner has no contributing diagnosis, though success rates are generally lower than IVF.
- IVF with conventional fertilization — appropriate when sperm parameters are mildly impaired and total motile sperm count is adequate.
- IVF with ICSI — widely used when sperm parameters are significantly impaired or when prior fertilization failure has occurred. ASRM guidance does not recommend ICSI for non-male factor cases.
- Surgical sperm retrieval (TESE, micro-TESE, PESA) — required when no sperm are present in the ejaculate.
- Donor sperm — appropriate when surgical retrieval is not successful, in cases of certain genetic conditions, or based on patient preference.
The right combination depends on the specifics of the diagnosis, partner factors, age, and patient preferences. These decisions are made with a reproductive endocrinologist and, often, a urologist with fertility training.
Questions to ask your fertility specialist
If male factor is part of your evaluation, the following questions can help structure the conversation:
- What specific parameters of the semen analysis are abnormal, and how far outside reference ranges?
- Is a repeat semen analysis recommended before treatment decisions?
- Is referral to a urologist with fertility training recommended in our case?
- Have we evaluated for varicocele, hormonal causes, or genetic factors that could be addressed?
- Given our specific situation, what do you see as the relative trade-offs between IUI, IVF without ICSI, and IVF with ICSI?
- If ICSI is recommended, what is your fertilization rate per ICSI cycle for our age group?
- How do you handle decisions if no mature sperm are recovered on the day of retrieval?
US fertility clinics with the highest reported male factor cycle volume
The list below ranks US fertility clinics by estimated annual cycles citing male factor as a diagnosis, derived from each clinic's CDC-reported total cycle count multiplied by the percentage of cycles citing this diagnosis. Volume is a signal that a clinic regularly treats this diagnosis. It is not a measure of success rate or quality. CDC does not publish per-diagnosis success rates at the clinic level, so a "best clinic for male factor" cannot be derived from this dataset alone.
How we computed these numbers
The clinic-level numbers on this page come from the CDC's National ART Surveillance System (NASS), specifically the 2022 ART Surveillance Report, which is the most recent dataset available. CDC publishes these reports on a two-year lag.
Estimated annual cycles for this diagnosis are computed by multiplying each clinic's total reported cycles by the percentage of cycles in which male factor was cited as a diagnosis. The CDC reports these percentages but does not publish absolute cycle counts per diagnosis, so the figures here are estimates.
A single IVF cycle can have multiple diagnoses recorded. A patient with both male factor and diminished ovarian reserve would have both diagnoses counted, which is why the percentages reported by clinics often sum to more than 100%. The "share of all CDC IVF cycles" stat above is therefore an approximation of how often this diagnosis appears in any cycle's record, not a percentage of cycles where it is the sole cause.
Editorial content on this page was last reviewed on April 30, 2026. We aim to update each diagnosis page when major guidelines from ASRM, ACOG, AUA, the Endocrine Society, or related professional bodies are revised.
Sources
- AUA/ASRM. Diagnosis and Treatment of Infertility in Men: AUA/ASRM Guideline (2024 amendment).
- World Health Organization. WHO laboratory manual for the examination and processing of human semen, 6th edition (2021).
- Practice Committee of the American Society for Reproductive Medicine. The use of intracytoplasmic sperm injection (ICSI) for non-male factor indications: a committee opinion.
- Centers for Disease Control and Prevention. 2022 Assisted Reproductive Technology National Summary Report.